CLINICAL ROLE -
Opinion
Video
Panelists summarize key takeaways on using bispecific antibodies for multiple myeloma treatment.
Emerging Bispecific T-Cell Engagers in Myeloma: Promises and Hurdles
The AQUILA Debate: Daratumumab for Treatment of Smoldering Multiple Myeloma
Nivolumab May Restore T-Cell Fitness Following CAR T-Cell Therapy in Patients With Multiple Myeloma
Pharmacy Focus: Oncology Edition - Consider Treatment Sequences Carefully in Myeloma
BCMA-Targeting CAR T-Cell Therapy Is Feasible in Patients With Multiple Myeloma and CNS Involvement
Elotuzumab-Based Regimen Demonstrates Efficacy in Relapsed/Refractory Multiple Myeloma